fda compounding semaglutide crackdown october 2025 The is drawing a harder line on compounded weight loss drug marketing. In the May–June 2026 issue of Dispense Times, this article breaks down key violations cited in recent FDA enforcement Beyond the Headlines: FDA Warning
Description
But check for any cracks in the glass, particularly hairline fractures that might not be immediately visible

Eli Lilly's savings card for Zepbound offers the same discount as it does for Mounjaro: a price as low as $25 per month for commercially insured patients with coverage for Zepbound

It emphasizes affordability and remote consultations but does not currently integrate genetic predisposition testing into its treatment model

Talk to your doctor if prescription medications appear to cause symptoms of heart palpitations
Extending its lead across formats and innovation, 20K consumers are already on Lillys oral GLP-1 pill Foundayo, while next-gen obesity drug retatrutide is advancing through trials

At those levels, the gastrointestinal effects, slowed motility, delayed gastric emptying, and nausea, shouldnt surprise us